FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205473714> ?p ?o ?g. }

• W4205473714 abstract "Abstract Background Clinical trials are underway to treat familial frontotemporal lobar degeneration (f‐FTLD). This is a rare disease, and a limited number of mutation carriers have been identified; thus, efficient trial design is critical. Multimodal, latent disease progression models (DPM) can estimate time to symptom onset and define the temporal ordering of biomarker changes. DPMs can also be leveraged to select endpoints and potentially supplement analyses by integrating historical data. Recent draft FDA guidance for gene therapy trials in neurological disease supports these novel approaches to clinical trials. Method Participants included 1,049 members of families affected by f‐FTLD, due to mutations in GRN , MAPT , or C9orf72 genes, who were enrolled in ALLFTD or GENFI. A Bayesian repeated measures model incorporated multimodal data to estimate disease progression, conditional on latent disease age (proximity to symptom onset), in 677 mutations carriers ( GRN (n=233), MAPT (n=151) and C9orf72 (n=293)). Family members without pathogenic mutations were used as the reference group. Mean follow‐up was 1.1 (SD=1.1) years. Jointly modeled longitudinal variables included neuropsychological scores, CDR®+NACC‐FTLD Box Score, MRI volumes of brain regions affected by f‐FTLD, and plasma levels of neurofilament light chain (NfL). Result Disease progression curves were similar across ALLFTD and GENFI cohorts. Plasma NfL elevations occurred earliest, up to 10 years before symptom onset, and NfL was the most powerful endpoint in the asymptomatic stage. MRI abnormalities occurred next, closer to symptom onset. The earliest MRI changes relative to symptom onset were observed in C9orf72 +. GRN mutation carriers showed the most rapid acceleration in all biomarkers, and this acceleration occurred in close proximity to symptom onset. Neuropsychological measures and CDR®+NACC‐FTLD Box Score were among the most promising endpoints in the symptomatic stage. Trial simulations indicated that using latent disease age as an enrollment criterion would allow some asymptomatic mutation carriers to be enrolled without sacrificing power. Conclusion Similarity in disease progression across ALLFTD and GENFI participants suggests these models will apply to international trials. Model‐derived estimates of disease progression curves indicate that endpoint selection should be specific to disease stage and mutation, and DPMs would facilitate greater participant enrollment." @default.
• W4205473714 created "2022-01-25" @default.
• W4205473714 creator A5007616908 @default.
• W4205473714 creator A5012478494 @default.
• W4205473714 creator A5013941877 @default.
• W4205473714 creator A5014014315 @default.
• W4205473714 creator A5019555711 @default.
• W4205473714 creator A5022632599 @default.
• W4205473714 creator A5022955585 @default.
• W4205473714 creator A5035435602 @default.
• W4205473714 creator A5037972521 @default.
• W4205473714 creator A5042212695 @default.
• W4205473714 creator A5056503861 @default.
• W4205473714 creator A5057656507 @default.
• W4205473714 creator A5058278504 @default.
• W4205473714 creator A5065322925 @default.
• W4205473714 creator A5066352714 @default.
• W4205473714 creator A5068882196 @default.
• W4205473714 creator A5070002346 @default.
• W4205473714 creator A5070348432 @default.
• W4205473714 creator A5072009949 @default.
• W4205473714 creator A5072143515 @default.
• W4205473714 creator A5073371346 @default.
• W4205473714 creator A5073802129 @default.
• W4205473714 creator A5075932767 @default.
• W4205473714 creator A5081296383 @default.
• W4205473714 creator A5086394733 @default.
• W4205473714 creator A5088826332 @default.
• W4205473714 creator A9999999999 @default.
• W4205473714 date "2021-12-01" @default.
• W4205473714 modified "2023-09-27" @default.
• W4205473714 title "Disease progression models of familial frontotemporal lobar degeneration and the temporal ordering of biomarker changes in an international cohort" @default.
• W4205473714 doi "https://doi.org/10.1002/alz.055353" @default.
• W4205473714 hasPublicationYear "2021" @default.
• W4205473714 type Work @default.
• W4205473714 citedByCount "0" @default.
• W4205473714 crossrefType "journal-article" @default.
• W4205473714 hasAuthorship W4205473714A5007616908 @default.
• W4205473714 hasAuthorship W4205473714A5012478494 @default.
• W4205473714 hasAuthorship W4205473714A5013941877 @default.
• W4205473714 hasAuthorship W4205473714A5014014315 @default.
• W4205473714 hasAuthorship W4205473714A5019555711 @default.
• W4205473714 hasAuthorship W4205473714A5022632599 @default.
• W4205473714 hasAuthorship W4205473714A5022955585 @default.
• W4205473714 hasAuthorship W4205473714A5035435602 @default.
• W4205473714 hasAuthorship W4205473714A5037972521 @default.
• W4205473714 hasAuthorship W4205473714A5042212695 @default.
• W4205473714 hasAuthorship W4205473714A5056503861 @default.
• W4205473714 hasAuthorship W4205473714A5057656507 @default.
• W4205473714 hasAuthorship W4205473714A5058278504 @default.
• W4205473714 hasAuthorship W4205473714A5065322925 @default.
• W4205473714 hasAuthorship W4205473714A5066352714 @default.
• W4205473714 hasAuthorship W4205473714A5068882196 @default.
• W4205473714 hasAuthorship W4205473714A5070002346 @default.
• W4205473714 hasAuthorship W4205473714A5070348432 @default.
• W4205473714 hasAuthorship W4205473714A5072009949 @default.
• W4205473714 hasAuthorship W4205473714A5072143515 @default.
• W4205473714 hasAuthorship W4205473714A5073371346 @default.
• W4205473714 hasAuthorship W4205473714A5073802129 @default.
• W4205473714 hasAuthorship W4205473714A5075932767 @default.
• W4205473714 hasAuthorship W4205473714A5081296383 @default.
• W4205473714 hasAuthorship W4205473714A5086394733 @default.
• W4205473714 hasAuthorship W4205473714A5088826332 @default.
• W4205473714 hasAuthorship W4205473714A9999999999 @default.
• W4205473714 hasBestOaLocation W42054737142 @default.
• W4205473714 hasConcept C126322002 @default.
• W4205473714 hasConcept C143998085 @default.
• W4205473714 hasConcept C2776939681 @default.
• W4205473714 hasConcept C2777898937 @default.
• W4205473714 hasConcept C2778641062 @default.
• W4205473714 hasConcept C2779134260 @default.
• W4205473714 hasConcept C2779483572 @default.
• W4205473714 hasConcept C2781197716 @default.
• W4205473714 hasConcept C535046627 @default.
• W4205473714 hasConcept C54355233 @default.
• W4205473714 hasConcept C71924100 @default.
• W4205473714 hasConcept C72563966 @default.
• W4205473714 hasConcept C86803240 @default.
• W4205473714 hasConceptScore W4205473714C126322002 @default.
• W4205473714 hasConceptScore W4205473714C143998085 @default.
• W4205473714 hasConceptScore W4205473714C2776939681 @default.
• W4205473714 hasConceptScore W4205473714C2777898937 @default.
• W4205473714 hasConceptScore W4205473714C2778641062 @default.
• W4205473714 hasConceptScore W4205473714C2779134260 @default.
• W4205473714 hasConceptScore W4205473714C2779483572 @default.
• W4205473714 hasConceptScore W4205473714C2781197716 @default.
• W4205473714 hasConceptScore W4205473714C535046627 @default.
• W4205473714 hasConceptScore W4205473714C54355233 @default.
• W4205473714 hasConceptScore W4205473714C71924100 @default.
• W4205473714 hasConceptScore W4205473714C72563966 @default.
• W4205473714 hasConceptScore W4205473714C86803240 @default.
• W4205473714 hasIssue "S5" @default.
• W4205473714 hasLocation W42054737141 @default.
• W4205473714 hasLocation W42054737142 @default.
• W4205473714 hasLocation W42054737143 @default.
• W4205473714 hasLocation W42054737144 @default.
• W4205473714 hasOpenAccess W4205473714 @default.
• W4205473714 hasPrimaryLocation W42054737141 @default.
• W4205473714 hasRelatedWork W1026354917 @default.
• W4205473714 hasRelatedWork W1969669833 @default.

• next